Ellington Management Group’s TherapeuticsMD TXMD Stock Holding History

Ellington Management Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-582	Closed	-$142K	–	783
2019 Q1	$142K	Buy	+582	New	+$154K	0.03%	507
2018 Q4	–	Sell	-1,280	Closed	-$420K	–	604
2018 Q3	$420K	Buy	+1,280	New	+$392K	0.11%	240
2018 Q2	–	Sell	-1,052	Closed	-$256K	–	861
2018 Q1	$256K	Buy	+1,052	New	+$295K	0.02%	650
2017 Q2	–	Sell	-834	Closed	-$300K	–	914
2017 Q1	$300K	Sell	834 -490	-37%	-$152K	0.01%	467
2016 Q4	$382K	Buy	+1,324	New	+$410K	0.06%	278
2016 Q1	–	Sell	-252	Closed	-$131K	–	709
2015 Q4	$131K	Buy	+252	New	+$93K	0.05%	521

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's TXMD Position: Q2 2019 in Review

Ellington Management Group sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 582 shares — an estimated $142K sold.

Ellington Management Group first reported a position in TXMD in Q4 2015 and held it in 6 quarters. The position peaked at $420K in Q3 2018. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Ellington Management Group reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
Ellington Management Group sold 582 TherapeuticsMD shares in Q2 2019, an estimated $142K.
Ellington Management Group first reported a position in TherapeuticsMD in Q4 2015 and held it in 6 quarters.
Ellington Management Group's TherapeuticsMD position peaked at $420K in Q3 2018.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.